PBYI
Puma Biotechnology, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-08 12:48 UTC
Last close
10.69USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-26
13.3xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
25.1%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
13.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
18.3%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
0.22Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Growth is the furthest below its sector's middle: 0.32 against 0.50 on the market's range.
- Growth0.3%32 of 100, below its sector
- Returns on capital25.1%91 of 100, above its sector
- Margins74.5%82 of 100, above its sector
- Price13.3x58 of 100, above its sector
- Safety0.2248 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 4 of 4- Profit on each unit of sales13.6%52.3%Behind
Higher is better here.
- Return on the capital it uses25.1%n/an/a
Higher is better here.
- Sales growth over five years0.3%320%Behind
Higher is better here.
- Debt against equity0.22n/an/a
Lower is better here.
- Gross margin74.5%88.5%Behind
Higher is better here.
- Price against earnings13.3x2.4xBehind
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against CorMedix Inc., PBYI is behind on 4 of 4 measures.
Against CorMedix Inc., PBYI is behind on 4 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-26
Profit on each unit of sales13.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
Return on the capital it uses25.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
Sales growth over five years0.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
Debt against equity0.22
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
Gross margin74.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD
Price against earnings13.3x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001437749-26-005891
- Reported in
- USD